SEQUENOM and Iceland Genomics Announce Research Collaboration to Investigate Role of Cancer Predisposition Genes

San Diego, California and Reykjavik, Iceland (ots/PRNewswire) -

- Continues Research to Validate Significance of SEQUENOM'sPortfolio of Breast Cancer Genetic Discoveries

SEQUENOM, Inc. (NASDAQ: SQNM) and Iceland Genomics Corporation(Iceland Genomics), a privately-held company, entered into a researchcollaboration to analyze SEQUENOM's proprietary panels of geneticmarkers associated with breast and prostate cancer in Icelandicpatient samples. The results of this collaboration could providefurther validation of SEQUENOM's genetic markers predisposing forbreast and prostate cancer, and improve the understanding of the roleof these genetic markers in disease onset, progression andtherapeutic response.

SEQUENOM's proprietary genetic markers were discovered through aseries of genome-wide association studies and subsequently replicatedin multiple independent clinical collections. Among the markers to bestudied in the Icelandic population are SNPs (single nucleotidepolymorphisms) from the ICAM and the NuMA gene regions. SEQUENOM andIceland Genomics will jointly analyze the resulting data to determineto what extent SEQUENOM's disease predisposition markers areassociated with specific clinical endpoints.

"The collaboration between our two companies may lead to importantbreast and prostate cancer diagnostic and prognostic applications inthe field of molecular medicine. The study should provide insight towhat extent genetic markers that predispose an individual to a higherdisease risk affect disease progression and therapeutic outcome,"stated Steve Zaniboni, SEQUENOM's acting Chief Executive Officer."SEQUENOM has identified and validated more than 60 high confidencecandidate gene regions in 11 major disease areas. This collaborationis part of a program to establish the diagnostic value of SEQUENOM'sdisease gene portfolio beyond disease predisposition."

"Iceland is a very exciting and rewarding place for performinggenetic analysis of complex diseases such as cancer. Comprehensiveclinical data combined with the participation and goodwill ofIcelanders and the clinical community provides an unparalleled basisfor a successful research effort," said Dana Hosseini, IcelandGenomics' Chief Executive Officer. "This agreement is part of ourlong term strategic effort to utilize our cancer research program todevelop results that can be translated into therapeutic benefits forcancer patients."

Iceland Genomics will utilize its large collections of breast andprostate cancer patient samples and clinical databases to test andvalidate SEQUENOM's markers. The results of the collaboration areexpected to increase the utility and value of Iceland Genomics'cancer genomic database. SEQUENOM has commercialization rights forproducts developed as a result of the collaboration and IcelandGenomics is entitled to receive royalties from sales of thoseproducts.

About Iceland Genomics Corporation

Iceland Genomics Corporation (Iceland Genomics) is a privatelyheld cancer biology company using an innovative 'clinical genomics'approach to understand the underlying mechanisms of cancer, isolateand characterize new therapeutic targets for cancer, assess outcomesof specific therapies in genetically defined subcategories of cancerpatients and optimize clinical trials for success. Iceland Genomicswas incorporated in the State of Delaware in October 1998, and is thesole owner of an Icelandic subsidiary called UVS. Iceland Genomics isone of several genomics-based biotechnology companies operating inIceland and the only company that solely focuses on cancer biology.


SEQUENOM is committed to providing the best genetic analysisproducts that translate genomic science into superior solutions forbiomedical research, molecular medicine and agriculturalapplications. The Company's proprietary MassARRAY system is ahigh-performance DNA analysis platform that efficiently and preciselymeasures the amount of genetic target material and variationstherein. The system is able to deliver reliable and specific datafrom complex biological samples and from genetic target material thatis only available in trace amounts.

SEQUENOM(R) and MassARRAY(R) are registered trademarks ofSEQUENOM, Inc.

ots Originaltext: Sequenom, Inc.Im Internet recherchierbar: http://www.presseportal.de

Contact:Amy Caterina, SEQUENOM, Inc., Investor Relations, +1-858-202-9033, acaterina@sequenom.com; Dana Hosseini, Iceland Genomics Corporation, Chief Executive Officer, +354-525-3615, dhosseini@uvs.is

Sequenom, Inc.

Zurück zur Übersiche Medizin-Nachrichten

Preisvergleich Medikamente
Medikament oder PZN:   
In Zusammenarbeit mit Medizinfuchs


SEQUENOM and Iceland Genomics Announce Research Collaboration to Investigate Role of Cancer Predisposition Genes